An Early Phase 1 interventional study of GI001 in B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia, sponsored by Hematology department of the 920th hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Hematology department of the 920th hospital · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.
Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 203rd largest by planned enrollment of the 273 interventional ones that give a count, is one of 41 that started in 2025, is one of 124 in phase 1, reaches primary completion later than 95 of the 145 other live ones, and was the 282nd registered.
889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.
Browse Lymphoma, B-Cell studies →125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:
UCARsgen Biotech Limited · Sites in China
Ages 18–75
Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · Sites in China
Ages 18–75
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18+
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Sites in China
Ages 18+
Chinese PLA General Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 182 · Phase 2 110 · Phase 3 20 · Phase 4 7
First in 2006; this study’s year is marked. 41 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 34 across 775 interventional studies indexed under Lymphoma, B-Cell.
Median enrollment 30 across the 273 interventional studies, 175 across the 10 observational. Of the 40 that completed or were terminated, 7 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 283 have an industry lead sponsor. The 10 most frequent:
Hematology department of the 920th hospital is the lead sponsor of 10 studies on the registry; 7 are open to participants now.
Hematology department of the 920th hospital has 1 study filed under Lymphoma, B-Cell — fewer than ten, so there is no comparison to draw.
43 of the studies in Lymphoma, B-Cell with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT06047080Phase 3Hoffmann-La RocheAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | 2027-10-01 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT06445517InSilico Medicine Hong Kong LimitedStudy Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 283 studies in Lymphoma, B-Cell with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multi-cohort, investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of GI001 in adult patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL) and B-cell Acute Lymphoblastic Leukemia (R/R B-ALL).
GI001 is an exploratory, in vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting the CD19 antigen. Unlike traditional CAR-T cell therapies that require extensive in vitro cell manufacturing, GI001 is administered directly to the patient via intravenous infusion, aiming to generate CAR-T cells directly within the patient's body.
The study consists of two main phases:
The primary focus of the study is to continuously monitor adverse events and evaluate the overall safety profile. Secondary objectives include assessing clinical response rates (such as Objective Response Rate and Complete Response Rate), survival outcomes, and the expansion levels of CAR-T cells in the peripheral blood.
This is an open-label, multi-cohort, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and preliminary efficacy of GI001 in adult patients with R/R B-NHL and R/R B-ALL. The study is divided into a Dose-Escalation Phase and a potential Dose-Expansion Phase.
Dose-Escalation Phase
Dose-Expansion Phase
Study Procedures
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Age 18 to 75 years, inclusive.
Exclusion Criteria:
1. Prior antitumor therapy as follows (except agents proven to enhance CAR-T cell efficacy or not to affect CAR-T cells, after an appropriate ):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intravenous infusion of GI001, an in vivo CD19-targeted CAR-T therapy, at dose level -1 (3.5x10\^8 TU; TU = transducing units). Premedication with intramuscular promethazine 25 mg or diphenhydramine 20 mg is recommended 15-30 minutes before infusion. Infusion duration does not exceed 2 hours. No lymphodepleting conditioning is specified in the protocol. This dose level is explored only if a safety signal is observed at the starting dose.
Biological: GI001
Single intravenous infusion of GI001, an in vivo CD19-targeted CAR-T therapy, at dose level 1 (7.0x10\^8 TU), the starting dose. Premedication with intramuscular promethazine 25 mg or diphenhydramine 20 mg is recommended 15-30 minutes before infusion. Infusion duration does not exceed 2 hours. No lymphodepleting conditioning is specified in the protocol. Enrollment follows a 3+3 dose-escalation design: the first participant is observed for at least 2 weeks before the next participants are enrolled.
Biological: GI001
Single intravenous infusion of GI001, an in vivo CD19-targeted CAR-T therapy, at dose level 2 (1.0x10\^9 TU). Premedication with intramuscular promethazine 25 mg or diphenhydramine 20 mg is recommended 15-30 minutes before infusion. Infusion duration does not exceed 2 hours. No lymphodepleting conditioning is specified in the protocol. Escalation to this dose level occurs if no DLT is observed at the previous dose level.
Biological: GI001
GI001 is an in vivo CD19-targeted CAR-T therapy. It is a lentiviral vector-based product using a third-generation self-inactivating lentiviral vector system with a five-plasmid packaging design. GI001 is administered by intravenous injection and delivers the CD19 CAR gene directly into the patient, reprogramming the patient's own T cells in situ to express CD19 CAR without ex vivo cell manufacturing. No lymphodepleting conditioning is required, and a single injection is given. GI001 is supplied as a colorless to slightly opaque liquid, 1 mL per vial, stored at -70 +/- 10 degrees C. Infusion duration does not exceed 2 hours. Dose levels evaluated in this study are 3.5x10\^8 TU, 7.0x10\^8 TU and 1.0x10\^9 TU (TU = transducing units). Recommended premedication is intramuscular promethazine 25 mg or diphenhydramine 20 mg given 15-30 minutes before infusion. Dose modification is not permitted (a +/-20% dose range is acceptable).
Incidence and severity of adverse events (AEs)
Incidence, severity, seriousness, and relationship to GI001 of treatment-emergent adverse events and serious adverse events. Severity graded per NCI CTCAE v6.0. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) graded per ASTCT 2019 consensus criteria; immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) graded per ASTCT 2023 criteria.
Time frame: From baseline through 2 years after GI001 administration
Change from baseline in body temperature
Change from baseline in body temperature, measured in degrees Celsius, at each scheduled post-dose assessment.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Percentage of participants with dose-limiting toxicities (DLTs)
Percentage of participants in the DLT analysis set who experience at least one protocol-defined DLT within 28 days after GI001 administration. The analysis set includes participants who complete DLT assessment or experience a DLT during the assessment period. DLTs are treatment-related toxicities defined in Protocol Section 4.1.4, including qualifying cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, infusion-related hypersensitivity, non-hematologic toxicities, neutropenia with severe infection, thrombocytopenia with qualifying bleeding, and grade 5 toxicity. Protocol-specified severity thresholds, recovery criteria, and exclusions apply. The number and percentage of participants with DLTs will be summarized.
Time frame: From GI001 administration through 28 days after administration
Maximum tolerated dose (MTD)
The highest GI001 dose level, expressed in transducing units (TU), at which no more than 1 of 6 evaluable participants experiences a protocol-defined dose-limiting toxicity (DLT) during the 28-day observation period after administration. If only 3 participants have been enrolled at the candidate MTD, 3 additional participants are enrolled for confirmation. The MTD is determined from the dose-escalation cohort data.
Time frame: From GI001 administration through 28 days after administration for each participant in the dose-escalation phase
Recommended dose for expansion (RDE)
GI001 dose level(s), expressed in transducing units (TU), selected for expansion by the Safety Review Committee based on available safety, tolerability, preliminary efficacy, pharmacokinetic, pharmacodynamic, and immunogenicity data from the dose-escalation phase.
Time frame: From GI001 administration through 90 days after administration for each participant in the dose-escalation phase
Change from baseline in systolic blood pressure
Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg), at each scheduled post-dose assessment.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in pulse rate
Change from baseline in pulse rate, measured in beats per minute, at each scheduled post-dose assessment.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in respiratory rate
Change from baseline in respiratory rate, measured in breaths per minute, at each scheduled post-dose assessment.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in ECOG performance status score
Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status score at each scheduled post-dose assessment. Scores range from 0 (fully active) to 5 (death), with higher scores indicating worse performance status.
Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in heart rate measured by 12-lead ECG
Change from baseline in heart rate, measured in beats per minute by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.
Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in PR interval measured by 12-lead ECG
Change from baseline in PR interval, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.
Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in R-R interval measured by 12-lead ECG
Change from baseline in R-R interval, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.
Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in diastolic blood pressure
Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg), at each scheduled post-dose assessment.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in QRS duration measured by 12-lead ECG
Change from baseline in QRS duration, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.
Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in QT interval measured by 12-lead ECG
Change from baseline in QT interval, measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.
Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in QTcF interval measured by 12-lead ECG
Change from baseline in QT interval corrected for heart rate using the Fridericia formula (QTcF), measured in milliseconds by 12-lead electrocardiogram (ECG), at each scheduled post-dose assessment. QTcF = QT / (RR in seconds)\^(1/3). After at least 10 minutes of rest, three measurements are obtained within 5 minutes and averaged.
Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Number of participants by change from baseline in physical examination findings
Physical examination findings are classified as normal or abnormal by the investigator. The number of participants in each baseline-to-post-dose category (normal to normal, normal to abnormal, abnormal to normal, or abnormal to abnormal) will be summarized by examined body system and scheduled visit. Examinations cover the head, eyes, ears, nose, throat, neck, heart, chest including lungs, abdomen, extremities, skin, lymph nodes, nervous system, and general condition. Post-dose examinations may focus on clinically indicated organs and systems, as specified in the protocol.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Number of participants by change from baseline in overall 12-lead ECG assessment
The overall 12-lead electrocardiogram (ECG) assessment is classified as normal or abnormal by the investigator. The number of participants in each baseline-to-post-dose category (normal to normal, normal to abnormal, abnormal to normal, or abnormal to abnormal) will be summarized at each scheduled post-dose assessment. This outcome describes the overall ECG interpretation; quantitative ECG parameters are reported separately.
Time frame: Baseline and Days 14, 28, 60, and 90, and Months 6, 9, 12, 18, and 24 after GI001 administration
Change from baseline in red blood cell count
Change from baseline in red blood cell count, measured in 10\^12/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in hemoglobin concentration
Change from baseline in hemoglobin concentration, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in hematocrit
Change from baseline in hematocrit, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in white blood cell count
Change from baseline in white blood cell count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in platelet count
Change from baseline in platelet count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in absolute neutrophil count
Change from baseline in absolute neutrophil count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in absolute lymphocyte count
Change from baseline in absolute lymphocyte count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in absolute monocyte count
Change from baseline in absolute monocyte count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in absolute eosinophil count
Change from baseline in absolute eosinophil count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in absolute basophil count
Change from baseline in absolute basophil count, measured in 10\^9/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in neutrophil percentage
Change from baseline in neutrophil percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in lymphocyte percentage
Change from baseline in lymphocyte percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in monocyte percentage
Change from baseline in monocyte percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in eosinophil percentage
Change from baseline in eosinophil percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in basophil percentage
Change from baseline in basophil percentage, measured in %, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall. Changes are expressed in percentage points.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in alanine aminotransferase (ALT)
Change from baseline in alanine aminotransferase (ALT), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in aspartate aminotransferase (AST)
Change from baseline in aspartate aminotransferase (AST), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in gamma-glutamyl transferase (GGT)
Change from baseline in gamma-glutamyl transferase (GGT), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in alkaline phosphatase (ALP)
Change from baseline in alkaline phosphatase (ALP), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in lactate dehydrogenase (LDH)
Change from baseline in lactate dehydrogenase (LDH), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in creatine kinase (CK)
Change from baseline in creatine kinase (CK), measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in creatine kinase-MB (CK-MB) activity
Change from baseline in creatine kinase-MB (CK-MB) activity, measured in U/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in total bilirubin
Change from baseline in total bilirubin, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in direct bilirubin
Change from baseline in direct bilirubin, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in creatinine
Change from baseline in creatinine, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in uric acid
Change from baseline in uric acid, measured in micromol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in glucose
Change from baseline in glucose, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in urea
Change from baseline in urea, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in potassium
Change from baseline in potassium, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in sodium
Change from baseline in sodium, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in chloride
Change from baseline in chloride, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in inorganic phosphorus
Change from baseline in inorganic phosphorus, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in total protein
Change from baseline in total protein, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in albumin
Change from baseline in albumin, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in globulin
Change from baseline in globulin, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in albumin-to-globulin ratio
Change from baseline in albumin-to-globulin ratio, measured in unitless, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in prothrombin time (PT)
Change from baseline in prothrombin time (PT), measured in seconds, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in activated partial thromboplastin time (APTT)
Change from baseline in activated partial thromboplastin time (APTT), measured in seconds, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in thrombin time (TT)
Change from baseline in thrombin time (TT), measured in seconds, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in fibrinogen
Change from baseline in fibrinogen, measured in g/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in international normalized ratio (INR)
Change from baseline in international normalized ratio (INR), measured in unitless, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in urine pH
Change from baseline in urine pH, measured in pH units, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in urine white blood cell count
Change from baseline in urine white blood cell count, measured in cells/microliter, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in urine red blood cell count
Change from baseline in urine red blood cell count, measured in cells/microliter, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in magnesium
Change from baseline in magnesium, measured in mmol/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in troponin concentration measured by chemiluminescence immunoassay
Change from baseline in troponin concentration measured by chemiluminescence immunoassay, measured in ng/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Change from baseline in D-dimer
Change from baseline in D-dimer, measured in mg/L, at each scheduled post-dose laboratory assessment. Change is calculated as the post-dose value minus the baseline value and summarized descriptively by dose level and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Number of participants by change from baseline in urine protein category
Number of participants in each baseline-to-post-dose category of urine protein at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Number of participants by change from baseline in urine glucose category
Number of participants in each baseline-to-post-dose category of urine glucose at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Number of participants by change from baseline in urine ketones category
Number of participants in each baseline-to-post-dose category of urine ketones at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Number of participants by change from baseline in urine urobilinogen category
Number of participants in each baseline-to-post-dose category of urine urobilinogen at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Number of participants by change from baseline in urine leukocyte esterase category
Number of participants in each baseline-to-post-dose category of urine leukocyte esterase at each scheduled laboratory assessment. Categories are the qualitative or semiquantitative results reported by the laboratory. Results are summarized as participant counts by baseline category, post-dose category, scheduled visit, and dose level, and overall.
Time frame: Baseline and scheduled post-dose assessments through 24 months after GI001 administration
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.
Of 117 non-industry phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's planned 24 months is below that.
Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 37 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hematology department of the 920th hospital